Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The influence of ketamine on drug discovery in depression
Christoph Kraus, Daniel Wasserman, Ioline D. Henter, et al.
Drug Discovery Today (2019) Vol. 24, Iss. 10, pp. 2033-2043
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Ketamine: A tale of two enantiomers
Luke A. Jelen, Allan H. Young, James Stone
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 109-123
Open Access | Times Cited: 163
Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin
Myles Corrigan, Aoife M. O’Rourke, Barry Moran, et al.
Neuronal Signaling (2023) Vol. 7, Iss. 2
Open Access | Times Cited: 47
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Ketamine for depression
Luke A. Jelen, James Stone
International Review of Psychiatry (2021) Vol. 33, Iss. 3, pp. 207-228
Closed Access | Times Cited: 70
Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial
Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 8, pp. 1574-1581
Open Access | Times Cited: 61
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Sophie Holmes, Sjoerd J. Finnema, Mika Naganawa, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 4, pp. 2273-2281
Open Access | Times Cited: 53
Targeting receptor complexes: a new dimension in drug discovery
Mette Ishoey, Louise S. Clemmensen, David S. Bredt, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 12, pp. 884-901
Closed Access | Times Cited: 66
Molecular, Structural, Functional, and Pharmacological Sites for Vesicular Glutamate Transporter Regulation
Nicolas Pietrancosta, Mahamadou Djibo, Stéphanie Daumas, et al.
Molecular Neurobiology (2020) Vol. 57, Iss. 7, pp. 3118-3142
Open Access | Times Cited: 52
Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects
Bhuvi Sachdeva, Punya Sachdeva, Shampa Ghosh, et al.
Ibrain (2023) Vol. 9, Iss. 1, pp. 90-101
Open Access | Times Cited: 19
Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression
Kelly E. Dunham, B. Jill Venton
Analytical and Bioanalytical Chemistry (2024) Vol. 416, Iss. 9, pp. 2301-2318
Open Access | Times Cited: 7
A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders
Susan Kim, Brittany S. Rush, Timothy Rice
European Child & Adolescent Psychiatry (2020) Vol. 30, Iss. 10, pp. 1485-1501
Closed Access | Times Cited: 48
BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model
Ling-Sha Ju, Jiaojiao Yang, Tingting Zhu, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants
Khushboo, Nikhat J. Siddiqi, Maria de Lourdes Pereira, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 6, pp. 3564-3584
Closed Access | Times Cited: 22
Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus
Mohammed E. A. Elhussiny, Giulia Carini, Jessica Mingardi, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 104, pp. 110033-110033
Open Access | Times Cited: 35
Novel Targets to Treat Depression: Opioid-Based Therapeutics
Caroline A. Browne, Moriah L. Jacobson, Irwin Lucki
Harvard Review of Psychiatry (2020) Vol. 28, Iss. 1, pp. 40-59
Closed Access | Times Cited: 34
Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression
Ashish Sahib, Joana Loureiro, Megha Vasavada, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 32
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
Roger S. McIntyre, Rakesh Jain
CNS Drugs (2024) Vol. 38, Iss. 11, pp. 869-890
Open Access | Times Cited: 4
Modulation of the functional connectome in major depressive disorder by ketamine therapy
Ashish Sahib, Joana Loureiro, Megha Vasavada, et al.
Psychological Medicine (2020) Vol. 52, Iss. 13, pp. 2596-2605
Open Access | Times Cited: 30
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Domenico De Berardis, Carmine Tomasetti, Maurizio Pompili, et al.
Current Topics in Medicinal Chemistry (2020) Vol. 20, Iss. 7, pp. 554-584
Closed Access | Times Cited: 28
A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants
Chadi G. Abdallah, Kyung-Heup Ahn, Lynnette A. Averill, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 2, pp. 478-485
Open Access | Times Cited: 28
The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
Gernot Fugger, Lucie Bartova, Chiara Fabbri, et al.
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 272, Iss. 4, pp. 715-727
Open Access | Times Cited: 18
Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine
Artemis Zavaliangos‐Petropulu, Noor Al‐Sharif, Brandon Taraku, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2022) Vol. 8, Iss. 4, pp. 361-386
Open Access | Times Cited: 18
Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychotic Symptoms
Joseph T. La Torre, Mehdi Mahammadli, Kyle T. Greenway, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 16
Proof‐of‐concept randomized controlled trial of single‐session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement
William S.H. Kim, Mikaela K. Dimick, Danielle Omrin, et al.
Bipolar Disorders (2022) Vol. 25, Iss. 3, pp. 221-232
Open Access | Times Cited: 16
Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
Lucie Bartova, Markus Dold, Gernot Fugger, et al.
Depression and Anxiety (2021) Vol. 38, Iss. 9, pp. 896-906
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top